Growth Metrics

Vertex Pharmaceuticals (VRTX) Income from Non-Controlling Interests (2016 - 2018)

Historic Income from Non-Controlling Interests for Vertex Pharmaceuticals (VRTX) over the last 8 years, with Q4 2018 value amounting to -$25.4 million.

  • Vertex Pharmaceuticals' Income from Non-Controlling Interests fell 179427.05% to -$25.4 million in Q4 2018 from the same period last year, while for Sep 2019 it was -$25.4 million, marking a year-over-year decrease of 24838.09%. This contributed to the annual value of -$9.8 million for FY2018, which is 9430.14% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Income from Non-Controlling Interests stood at -$25.4 million for Q4 2018, which was down 179427.05% from -$290000.0 recorded in Q3 2018.
  • In the past 5 years, Vertex Pharmaceuticals' Income from Non-Controlling Interests registered a high of $28.4 million during Q2 2016, and its lowest value of -$188.3 million during Q3 2017.
  • Over the past 5 years, Vertex Pharmaceuticals' median Income from Non-Controlling Interests value was -$98000.0 (recorded in 2015), while the average stood at -$10.7 million.
  • In the last 5 years, Vertex Pharmaceuticals' Income from Non-Controlling Interests skyrocketed by 574183.67% in 2016 and then tumbled by 2695675.29% in 2017.
  • Over the past 5 years, Vertex Pharmaceuticals' Income from Non-Controlling Interests (Quarter) stood at $4.2 million in 2014, then crashed by 122.39% to -$938000.0 in 2015, then tumbled by 452.88% to -$5.2 million in 2016, then skyrocketed by 128.94% to $1.5 million in 2017, then plummeted by 1794.27% to -$25.4 million in 2018.
  • Its Income from Non-Controlling Interests stands at -$25.4 million for Q4 2018, versus -$290000.0 for Q3 2018 and -$1.1 million for Q2 2018.